FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
75.23 USD
0.86 (1.14%)
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
607.64M
892.25M
1.06B
1.31B
1.43B
1.78B
2.22B
2.76B
3.44B
4.29B
29.18M
-54.96M
-9.98M
299.08M
320.56M
153.13M
190.78M
237.68M
296.12M
368.92M
-3.19M
-13.06M
-23.82M
-7.34M
-14.92M
-20.82M
-25.94M
-32.31M
-40.26M
-50.16M
25.98M
-68.02M
-33.8M
291.74M
305.64M
132.31M
164.84M
205.37M
255.86M
318.76M
-
-
-
-
-
-
-
-
-
-
-